Business
Partial Disposal of Shares in SkinBioTherapeutics
OptiBiotix Health plc has partially disposed of its shareholding in SkinBioTherapeutics plc, selling 7,500,000 ordinary shares for £675,000 in cash. These proceeds will be used for general working capital, extending the company's runway into the first half of 2027. Following this sale, OptiBiotix retains 5,700,000 ordinary shares in SkinBioTherapeutics, representing 2.2% of its total issued share capital. Disclaimer*
About this update from Optibiotix Health Plc
OptiBiotix Health plc ("OptiBiotix" or the "Company" or "the Group") Partial Disposal of Shareholding in SkinBioTherapeutics OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces that it has disposed of 7,500,000 ordinary shares in SkinBioTherapeutics plc (AIM:SBTX) ("SkinBioTherapeutics"), generating cash proceeds of £675,000 which will be used for the Company's general working capital purposes and are expected to provide the Company with working capital runway into H1 2027. Following the disposal, the Company's shareholding in SkinBioTherapeutics consists of 5,700,000 ordinary shares, representing 2.2% of the total issued share capital of SkinBioTherapeutics at the date of this announcement. This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement. For further information, please contact: OptiBiotix Health plc www.optibiotix.com Neil Davidson, Chairman Stephen O'Hara, Chief Executive Cairn Financial Advisers LLP (NOMAD and Broker) Tel: 020 7213 0880 Liam Murray / Ludovico Lazzaretti / James Western About OptiBiotix - www.optibiotix.com OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world. Caution regarding forward looking statements Certain statements in this announcement, are, or may be deemed to be, forward-looking statements. Forward-loo...
View stock analysis, news, and events for Optibiotix Health Plc